bis[(1R)-menthyl] carbonate | 201478-39-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: bis[(1R)-menthyl] carbonate
• 英文别名: carbonic acid di-((1R)-menthyl ester)；Kohlensaeure-di-((1R)-menthylester)；Di-((1R)-menthyl)-carbonat；di-l-menthyl carbonate；menthyl carbonate；bis[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] carbonate
• CAS: 201478-39-9
• 化学式: C₂₁H₃₈O₃
• 分子量: 338.531
• InChiKey: QFEHNMKROHXPFO-XRNRSJMDSA-N

物化性质

• 沸点：
  422.0±12.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  光气 、 L-薄荷醇 在 molecuar sieves 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 48.0h， 以85%的产率得到bis[(1R)-menthyl] carbonate
  参考文献：
  名称：

  通过酰化作用进行内酯动力学拆分 - 在 Estrane 衍生物的对映选择性合成中的应用

  摘要：

  过量的外消旋螺内酯 1 (6,9-divinyl-1-oxaspiro[4.4]nonan-2-one) 烯醇酯被保护的 (S)-乳酸甲酯或 (-)-冰片碳酸酯的酰化以动力学分辨率发生。所得内酯用 1-碘苯并环丁烯进行烷基化，得到可作为非外消旋类固醇前体的化合物，例如 11α-烷氧基羰基-11β,13β-(γ-碳内酯)-17β-vinylgonatri-1,3,5(10)-烯。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)

  DOI：

  10.1002/ejoc.200500380

文献信息

• SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS
  申请人：Dugar Sundeep

  公开号：US20140121367A1

  公开（公告）日：2014-05-01

  The present invention relates to the synthesis and application of novel chiral/achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.

  本发明涉及合成和应用新型手性/无手性取代甲基甲酰试剂来修饰药物和/或生物活性物质，以改变未经修饰的原始试剂的物理化学、生物学和/或药代动力学性质，从而得到改性后的化合物。
• Prodrug of amino acid derivative
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：US10464884B2

  公开（公告）日：2019-11-05

  Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.

  本发明提供了一种由通式（I-A）表示的氨基酸衍生物原药，它是第 2 组代谢谷氨酸受体拮抗剂的氨基酸衍生物的原药形式，或其药学上可接受的盐。 更具体地说，所提供的通式（I-A）所代表的氨基酸衍生物原药是一种预防或治疗药物，可用于治疗情绪障碍（包括抑郁症和双相情感障碍）、焦虑症、认知障碍、发育障碍、阿尔茨海默病、帕金森病、与肌肉僵硬相关的运动障碍、与肌肉僵硬有关的运动障碍、睡眠障碍、亨廷顿舞蹈症、饮食失调、药物依赖、癫痫、脑梗塞、脑缺血、脑供血不足、脑水肿、脊髓疾病、头部创伤、炎症和免疫相关疾病等。
• Prodrug amino acid derivative
  申请人：TAISHO PHARMACEUTICALS CO., LTD.

  公开号：US10689327B2

  公开（公告）日：2020-06-23

  Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.

  本发明提供了一种由通式（I-A）表示的氨基酸衍生物原药，它是第 2 组代谢谷氨酸受体拮抗剂的氨基酸衍生物的原药形式，或其药学上可接受的盐。 更具体地说，所提供的通式（I-A）所代表的氨基酸衍生物原药是一种预防或治疗药物，可用于治疗情绪障碍（包括抑郁症和双相情感障碍）、焦虑症、认知障碍、发育障碍、阿尔茨海默病、帕金森病、与肌肉僵硬相关的运动障碍、与肌肉僵硬有关的运动障碍、睡眠障碍、亨廷顿舞蹈症、饮食失调、药物依赖、癫痫、脑梗塞、脑缺血、脑供血不足、脑水肿、脊髓疾病、头部创伤、炎症和免疫相关疾病等。
• Process for producing blue microcapsules
  申请人：——

  公开号：US20020159957A1

  公开（公告）日：2002-10-31

  The invention relates to a process for producing uniformly colored blue microcapsules, using oil-soluble dyes.

  本发明涉及一种使用油溶性染料生产颜色均匀的蓝色微胶囊的工艺。
• Coated sherical seamless filled capsules
  申请人：Wonschik Jochen

  公开号：US20060110442A1

  公开（公告）日：2006-05-25

  Described is a spherical coated capsule comprising (a) a coating-free capsule having (i) a liquid or viscous core and (ii) a seamless solid shell surrounding this core, and (b) a seamless, solid coating surrounding said coating-free capsule, wherein—the diameter of the coated capsule is in the range of 5-9 mm, —the solid coating comprises at least one sugar or sugar-alcohol in an amount from about 30-90% (m/m), based on the total mass of the coated capsule, —the diameter of the coating-free capsule is in the range of 3-7 mm, the thickness of the shell of said coating-free capsule is in the range of 20-200 μm, —the ratio of shell thickness to diameter of said coating-free capsule is in the range of 0.004-0.04, —the shell of said coating-free capsule contains 70-90% (m/m) gelatine or alginate and 10-30% (m/m) plasticiser, based on the solids content of said shell, and —the core has a flavouring content in the range of 1-100% (m/m), based on the total mass of the core. Further described is a method for preparing such capsule.

  所述的球形包衣胶囊包括(a)无包衣胶囊，该无包衣胶囊具有(i)液体或粘性内核和(ii)围绕该内核的无缝固体外壳，以及(b)围绕所述无包衣胶囊的无缝固体包衣，其中，包衣胶囊的直径在 5-9 毫米之间、-所述固体涂层包含至少一种糖或糖-醇，其含量为涂布胶囊总质量的约 30-90%（m/m）， -所述无涂层胶囊的直径在 3-7 毫米的范围内，所述无涂层胶囊的外壳厚度在 20-200 μm 的范围内， -所述无涂层胶囊的外壳厚度与直径之比在 0.所述无包衣胶囊的外壳含有 70-90%（m/m）的明胶或海藻酸盐，以及 10-30%（m/m）的增塑剂（基于所述外壳的固体含量），以及--芯的香料含量在 1-100%（m/m）的范围内（基于芯的总质量）。进一步描述了制备这种胶囊的方法。